Author

Mi Na Kim

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Real-world outcomes of lenvatinib versus sorafenib as the second-line therapy after atezolizumab plus bevacizumab in patients with hepatocellular carcinoma: a large-scale multicenter study in Korea.

INTRODUCTION After first‑line atezolizumab plus bevacizumab (ATE + BEV) in hepatocellular carcinoma (HCC), optimal second‑line (2L) therapy remains unclear. This study compared the real‑world effectiveness and hepatotoxicity of lenvatinib versus sorafenib as 2L treatment after ATE + BEV. METHODS This retrospective, m...

Min-Ji Lee, Su-Bin Lim, J. Shim et al. · Hepatology International · 0 citations

Open access Aug 2026

The impact of alcohol consumption on the risk of hepatocellular carcinoma across different age groups: A nationwide cohort study

In this nationwide cohort of 3,869,084 adults, heavy alcohol consumption was associated with increased HCC risk in the 40–59-years and ≥60-years age groups, with the strongest association and highest 10-year cumulative risk observed among heavy drinkers aged ≥60 years.

Mi Na Kim, Kyungdo Han, Dong Yun Kim et al. · JHEP Reports · 0 citations